ORMP vs. ETTX, MITO, COCP, NLTX, ACIU, ANRO, TCRX, URGN, PSTX, and SNDL
Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Entasis Therapeutics (ETTX), Stealth BioTherapeutics (MITO), Cocrystal Pharma (COCP), Neoleukin Therapeutics (NLTX), AC Immune (ACIU), Alto Neuroscience (ANRO), TScan Therapeutics (TCRX), UroGen Pharma (URGN), Poseida Therapeutics (PSTX), and SNDL (SNDL). These companies are all part of the "medical" sector.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Entasis Therapeutics (NASDAQ:ETTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.
Oramed Pharmaceuticals has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Entasis Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
Oramed Pharmaceuticals' return on equity of -3.83% beat Entasis Therapeutics' return on equity.
Oramed Pharmaceuticals has higher earnings, but lower revenue than Entasis Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Entasis Therapeutics. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 0 mentions for Entasis Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 1.03 beat Entasis Therapeutics' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.
Oramed Pharmaceuticals received 219 more outperform votes than Entasis Therapeutics when rated by MarketBeat users. Likewise, 74.64% of users gave Oramed Pharmaceuticals an outperform vote while only 64.86% of users gave Entasis Therapeutics an outperform vote.
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.9% of Entasis Therapeutics shares are owned by institutional investors. 13.7% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 6.5% of Entasis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Oramed Pharmaceuticals beats Entasis Therapeutics on 13 of the 14 factors compared between the two stocks.
Get Oramed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oramed Pharmaceuticals Competitors List
Related Companies and Tools
